nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—migraine—Prednisone—systemic scleroderma	0.207	0.508	CpDpCtD
Naproxen—osteoarthritis—Prednisone—systemic scleroderma	0.2	0.492	CpDpCtD
Naproxen—UGT2B7—Mycophenolic acid—systemic scleroderma	0.0793	0.187	CbGbCtD
Naproxen—UGT1A1—Mycophenolic acid—systemic scleroderma	0.0686	0.162	CbGbCtD
Naproxen—UGT2B7—Mycophenolate mofetil—systemic scleroderma	0.0443	0.104	CbGbCtD
Naproxen—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.0383	0.0903	CbGbCtD
Naproxen—CYP2C8—Mometasone—systemic scleroderma	0.0282	0.0665	CbGbCtD
Naproxen—SLCO1A2—Prednisone—systemic scleroderma	0.0225	0.053	CbGbCtD
Naproxen—SLC22A6—Captopril—systemic scleroderma	0.0217	0.0511	CbGbCtD
Naproxen—ALB—Captopril—systemic scleroderma	0.0185	0.0435	CbGbCtD
Naproxen—CYP1A2—Pentoxifylline—systemic scleroderma	0.0147	0.0348	CbGbCtD
Naproxen—ALB—Mycophenolate mofetil—systemic scleroderma	0.0145	0.0342	CbGbCtD
Naproxen—CYP1A2—Leflunomide—systemic scleroderma	0.0141	0.0332	CbGbCtD
Naproxen—CYP2C9—Leflunomide—systemic scleroderma	0.0127	0.0299	CbGbCtD
Naproxen—ALB—Prednisone—systemic scleroderma	0.0116	0.0274	CbGbCtD
Naproxen—SLCO1A2—Methotrexate—systemic scleroderma	0.0113	0.0266	CbGbCtD
Naproxen—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0112	0.0265	CbGbCtD
Naproxen—SLC22A6—Methotrexate—systemic scleroderma	0.00684	0.0161	CbGbCtD
Naproxen—ALB—Methotrexate—systemic scleroderma	0.00583	0.0137	CbGbCtD
Naproxen—CYP2C9—cardial valve—systemic scleroderma	0.00557	0.298	CbGeAlD
Naproxen—PTGS2—skeletal joint—systemic scleroderma	0.00174	0.0933	CbGeAlD
Naproxen—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.000901	0.624	CbGdCrCtD
Naproxen—AKR1C3—smooth muscle tissue—systemic scleroderma	0.000788	0.0422	CbGeAlD
Naproxen—PTGS1—artery—systemic scleroderma	0.000763	0.0409	CbGeAlD
Naproxen—PTGS2—artery—systemic scleroderma	0.00073	0.0391	CbGeAlD
Naproxen—UGT2B7—digestive system—systemic scleroderma	0.000675	0.0361	CbGeAlD
Naproxen—PTGS1—endothelium—systemic scleroderma	0.000645	0.0345	CbGeAlD
Naproxen—PTGS2—endothelium—systemic scleroderma	0.000616	0.033	CbGeAlD
Naproxen—PTGS1—blood vessel—systemic scleroderma	0.000595	0.0318	CbGeAlD
Naproxen—AKR1C3—tendon—systemic scleroderma	0.000592	0.0317	CbGeAlD
Naproxen—UGT1A1—digestive system—systemic scleroderma	0.000574	0.0307	CbGeAlD
Naproxen—PTGS2—blood vessel—systemic scleroderma	0.000568	0.0304	CbGeAlD
Naproxen—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.000544	0.376	CbGdCrCtD
Naproxen—AKR1C3—lung—systemic scleroderma	0.00052	0.0278	CbGeAlD
Naproxen—SLCO1A2—digestive system—systemic scleroderma	0.000389	0.0208	CbGeAlD
Naproxen—SLCO1A2—lung—systemic scleroderma	0.000325	0.0174	CbGeAlD
Naproxen—PTGS1—connective tissue—systemic scleroderma	0.000305	0.0163	CbGeAlD
Naproxen—PTGS2—connective tissue—systemic scleroderma	0.000291	0.0156	CbGeAlD
Naproxen—PTGS1—smooth muscle tissue—systemic scleroderma	0.000279	0.0149	CbGeAlD
Naproxen—PTGS1—skin of body—systemic scleroderma	0.000275	0.0147	CbGeAlD
Naproxen—PTGS2—smooth muscle tissue—systemic scleroderma	0.000267	0.0143	CbGeAlD
Naproxen—PTGS2—skin of body—systemic scleroderma	0.000263	0.0141	CbGeAlD
Naproxen—CYP1A2—digestive system—systemic scleroderma	0.000254	0.0136	CbGeAlD
Naproxen—CYP2C9—digestive system—systemic scleroderma	0.000241	0.0129	CbGeAlD
Naproxen—PTGS1—digestive system—systemic scleroderma	0.00022	0.0118	CbGeAlD
Naproxen—CYP1A2—lung—systemic scleroderma	0.000212	0.0114	CbGeAlD
Naproxen—PTGS2—digestive system—systemic scleroderma	0.00021	0.0113	CbGeAlD
Naproxen—PTGS1—tendon—systemic scleroderma	0.00021	0.0112	CbGeAlD
Naproxen—PTGS2—tendon—systemic scleroderma	0.0002	0.0107	CbGeAlD
Naproxen—PTGS1—lung—systemic scleroderma	0.000184	0.00984	CbGeAlD
Naproxen—PTGS2—lung—systemic scleroderma	0.000176	0.00941	CbGeAlD
Naproxen—Chest pain—Mycophenolate mofetil—systemic scleroderma	5.06e-05	0.00034	CcSEcCtD
Naproxen—Myocardial infarction—Prednisone—systemic scleroderma	5.05e-05	0.000339	CcSEcCtD
Naproxen—Neuropathy peripheral—Prednisone—systemic scleroderma	5.05e-05	0.000339	CcSEcCtD
Naproxen—Breast disorder—Methotrexate—systemic scleroderma	5.05e-05	0.000339	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	5.04e-05	0.000339	CcSEcCtD
Naproxen—Anxiety—Mycophenolate mofetil—systemic scleroderma	5.04e-05	0.000339	CcSEcCtD
Naproxen—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	5.03e-05	0.000338	CcSEcCtD
Naproxen—Hypersensitivity—Azathioprine—systemic scleroderma	5.03e-05	0.000338	CcSEcCtD
Naproxen—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	5.02e-05	0.000337	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	5.02e-05	0.000337	CcSEcCtD
Naproxen—Insomnia—Lisinopril—systemic scleroderma	5.01e-05	0.000336	CcSEcCtD
Naproxen—Discomfort—Mycophenolate mofetil—systemic scleroderma	5e-05	0.000336	CcSEcCtD
Naproxen—Paraesthesia—Lisinopril—systemic scleroderma	4.97e-05	0.000334	CcSEcCtD
Naproxen—Vomiting—Captopril—systemic scleroderma	4.97e-05	0.000334	CcSEcCtD
Naproxen—Dry mouth—Mycophenolate mofetil—systemic scleroderma	4.95e-05	0.000332	CcSEcCtD
Naproxen—Dyspnoea—Lisinopril—systemic scleroderma	4.93e-05	0.000331	CcSEcCtD
Naproxen—Rash—Captopril—systemic scleroderma	4.93e-05	0.000331	CcSEcCtD
Naproxen—Dermatitis—Captopril—systemic scleroderma	4.92e-05	0.000331	CcSEcCtD
Naproxen—Somnolence—Lisinopril—systemic scleroderma	4.92e-05	0.00033	CcSEcCtD
Naproxen—Headache—Captopril—systemic scleroderma	4.9e-05	0.000329	CcSEcCtD
Naproxen—Confusional state—Mycophenolate mofetil—systemic scleroderma	4.89e-05	0.000328	CcSEcCtD
Naproxen—Dyspepsia—Lisinopril—systemic scleroderma	4.87e-05	0.000327	CcSEcCtD
Naproxen—Abdominal pain—Mycophenolic acid—systemic scleroderma	4.86e-05	0.000326	CcSEcCtD
Naproxen—Body temperature increased—Mycophenolic acid—systemic scleroderma	4.86e-05	0.000326	CcSEcCtD
Naproxen—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	4.85e-05	0.000326	CcSEcCtD
Naproxen—Oedema—Mycophenolate mofetil—systemic scleroderma	4.85e-05	0.000326	CcSEcCtD
Naproxen—Asthma—Methotrexate—systemic scleroderma	4.83e-05	0.000324	CcSEcCtD
Naproxen—Infection—Mycophenolate mofetil—systemic scleroderma	4.82e-05	0.000324	CcSEcCtD
Naproxen—Decreased appetite—Lisinopril—systemic scleroderma	4.81e-05	0.000323	CcSEcCtD
Naproxen—Eosinophilia—Methotrexate—systemic scleroderma	4.78e-05	0.000321	CcSEcCtD
Naproxen—Gastrointestinal disorder—Lisinopril—systemic scleroderma	4.78e-05	0.000321	CcSEcCtD
Naproxen—Fatigue—Lisinopril—systemic scleroderma	4.77e-05	0.00032	CcSEcCtD
Naproxen—Shock—Mycophenolate mofetil—systemic scleroderma	4.77e-05	0.00032	CcSEcCtD
Naproxen—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	4.76e-05	0.000319	CcSEcCtD
Naproxen—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	4.75e-05	0.000319	CcSEcCtD
Naproxen—Hypersensitivity—Leflunomide—systemic scleroderma	4.75e-05	0.000319	CcSEcCtD
Naproxen—Pancreatitis—Methotrexate—systemic scleroderma	4.74e-05	0.000318	CcSEcCtD
Naproxen—Constipation—Lisinopril—systemic scleroderma	4.73e-05	0.000318	CcSEcCtD
Naproxen—Pain—Lisinopril—systemic scleroderma	4.73e-05	0.000318	CcSEcCtD
Naproxen—Tachycardia—Mycophenolate mofetil—systemic scleroderma	4.73e-05	0.000318	CcSEcCtD
Naproxen—Skin disorder—Mycophenolate mofetil—systemic scleroderma	4.71e-05	0.000316	CcSEcCtD
Naproxen—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	4.69e-05	0.000315	CcSEcCtD
Naproxen—Diarrhoea—Azathioprine—systemic scleroderma	4.67e-05	0.000313	CcSEcCtD
Naproxen—Haemoglobin—Prednisone—systemic scleroderma	4.65e-05	0.000312	CcSEcCtD
Naproxen—Nausea—Captopril—systemic scleroderma	4.64e-05	0.000312	CcSEcCtD
Naproxen—Abdominal discomfort—Methotrexate—systemic scleroderma	4.63e-05	0.000311	CcSEcCtD
Naproxen—Haemorrhage—Prednisone—systemic scleroderma	4.63e-05	0.000311	CcSEcCtD
Naproxen—Anorexia—Mycophenolate mofetil—systemic scleroderma	4.62e-05	0.00031	CcSEcCtD
Naproxen—Asthenia—Leflunomide—systemic scleroderma	4.62e-05	0.00031	CcSEcCtD
Naproxen—Hallucination—Prednisone—systemic scleroderma	4.6e-05	0.000309	CcSEcCtD
Naproxen—Pancytopenia—Methotrexate—systemic scleroderma	4.59e-05	0.000308	CcSEcCtD
Naproxen—Feeling abnormal—Lisinopril—systemic scleroderma	4.56e-05	0.000306	CcSEcCtD
Naproxen—Pruritus—Leflunomide—systemic scleroderma	4.56e-05	0.000306	CcSEcCtD
Naproxen—Connective tissue disorder—Prednisone—systemic scleroderma	4.55e-05	0.000305	CcSEcCtD
Naproxen—Hypotension—Mycophenolate mofetil—systemic scleroderma	4.53e-05	0.000304	CcSEcCtD
Naproxen—Gastrointestinal pain—Lisinopril—systemic scleroderma	4.53e-05	0.000304	CcSEcCtD
Naproxen—Dysuria—Methotrexate—systemic scleroderma	4.52e-05	0.000303	CcSEcCtD
Naproxen—Dizziness—Azathioprine—systemic scleroderma	4.51e-05	0.000303	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	4.42e-05	0.000297	CcSEcCtD
Naproxen—Photosensitivity reaction—Methotrexate—systemic scleroderma	4.41e-05	0.000296	CcSEcCtD
Naproxen—Asthenia—Mycophenolic acid—systemic scleroderma	4.41e-05	0.000296	CcSEcCtD
Naproxen—Diarrhoea—Leflunomide—systemic scleroderma	4.41e-05	0.000296	CcSEcCtD
Naproxen—Urticaria—Lisinopril—systemic scleroderma	4.4e-05	0.000295	CcSEcCtD
Naproxen—Insomnia—Mycophenolate mofetil—systemic scleroderma	4.39e-05	0.000295	CcSEcCtD
Naproxen—Abdominal pain—Lisinopril—systemic scleroderma	4.38e-05	0.000294	CcSEcCtD
Naproxen—Body temperature increased—Lisinopril—systemic scleroderma	4.38e-05	0.000294	CcSEcCtD
Naproxen—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	4.35e-05	0.000292	CcSEcCtD
Naproxen—Pruritus—Mycophenolic acid—systemic scleroderma	4.35e-05	0.000292	CcSEcCtD
Naproxen—Vomiting—Azathioprine—systemic scleroderma	4.34e-05	0.000291	CcSEcCtD
Naproxen—Pneumonia—Methotrexate—systemic scleroderma	4.33e-05	0.000291	CcSEcCtD
Naproxen—Eye disorder—Prednisone—systemic scleroderma	4.32e-05	0.00029	CcSEcCtD
Naproxen—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	4.32e-05	0.00029	CcSEcCtD
Naproxen—Somnolence—Mycophenolate mofetil—systemic scleroderma	4.31e-05	0.00029	CcSEcCtD
Naproxen—Drowsiness—Methotrexate—systemic scleroderma	4.31e-05	0.000289	CcSEcCtD
Naproxen—Rash—Azathioprine—systemic scleroderma	4.3e-05	0.000289	CcSEcCtD
Naproxen—Dermatitis—Azathioprine—systemic scleroderma	4.3e-05	0.000289	CcSEcCtD
Naproxen—Depression—Methotrexate—systemic scleroderma	4.3e-05	0.000288	CcSEcCtD
Naproxen—Headache—Azathioprine—systemic scleroderma	4.27e-05	0.000287	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	4.27e-05	0.000287	CcSEcCtD
Naproxen—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	4.27e-05	0.000287	CcSEcCtD
Naproxen—Dizziness—Leflunomide—systemic scleroderma	4.26e-05	0.000286	CcSEcCtD
Naproxen—Renal failure—Methotrexate—systemic scleroderma	4.23e-05	0.000284	CcSEcCtD
Naproxen—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	4.22e-05	0.000283	CcSEcCtD
Naproxen—Diarrhoea—Mycophenolic acid—systemic scleroderma	4.2e-05	0.000282	CcSEcCtD
Naproxen—Stomatitis—Methotrexate—systemic scleroderma	4.2e-05	0.000282	CcSEcCtD
Naproxen—Angiopathy—Prednisone—systemic scleroderma	4.2e-05	0.000282	CcSEcCtD
Naproxen—Conjunctivitis—Methotrexate—systemic scleroderma	4.19e-05	0.000281	CcSEcCtD
Naproxen—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	4.19e-05	0.000281	CcSEcCtD
Naproxen—Immune system disorder—Prednisone—systemic scleroderma	4.18e-05	0.000281	CcSEcCtD
Naproxen—Pain—Mycophenolate mofetil—systemic scleroderma	4.15e-05	0.000279	CcSEcCtD
Naproxen—Constipation—Mycophenolate mofetil—systemic scleroderma	4.15e-05	0.000279	CcSEcCtD
Naproxen—Arrhythmia—Prednisone—systemic scleroderma	4.13e-05	0.000278	CcSEcCtD
Naproxen—Sweating—Methotrexate—systemic scleroderma	4.13e-05	0.000277	CcSEcCtD
Naproxen—Haematuria—Methotrexate—systemic scleroderma	4.11e-05	0.000276	CcSEcCtD
Naproxen—Vomiting—Leflunomide—systemic scleroderma	4.1e-05	0.000275	CcSEcCtD
Naproxen—Alopecia—Prednisone—systemic scleroderma	4.09e-05	0.000275	CcSEcCtD
Naproxen—Hypersensitivity—Lisinopril—systemic scleroderma	4.08e-05	0.000274	CcSEcCtD
Naproxen—Hepatobiliary disease—Methotrexate—systemic scleroderma	4.07e-05	0.000274	CcSEcCtD
Naproxen—Dizziness—Mycophenolic acid—systemic scleroderma	4.06e-05	0.000273	CcSEcCtD
Naproxen—Epistaxis—Methotrexate—systemic scleroderma	4.06e-05	0.000273	CcSEcCtD
Naproxen—Rash—Leflunomide—systemic scleroderma	4.06e-05	0.000273	CcSEcCtD
Naproxen—Dermatitis—Leflunomide—systemic scleroderma	4.06e-05	0.000273	CcSEcCtD
Naproxen—Mental disorder—Prednisone—systemic scleroderma	4.05e-05	0.000272	CcSEcCtD
Naproxen—Nausea—Azathioprine—systemic scleroderma	4.05e-05	0.000272	CcSEcCtD
Naproxen—Headache—Leflunomide—systemic scleroderma	4.04e-05	0.000271	CcSEcCtD
Naproxen—Erythema—Prednisone—systemic scleroderma	4.03e-05	0.000271	CcSEcCtD
Naproxen—Malnutrition—Prednisone—systemic scleroderma	4.03e-05	0.000271	CcSEcCtD
Naproxen—Agranulocytosis—Methotrexate—systemic scleroderma	4.02e-05	0.00027	CcSEcCtD
Naproxen—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	4e-05	0.000268	CcSEcCtD
Naproxen—Asthenia—Lisinopril—systemic scleroderma	3.97e-05	0.000267	CcSEcCtD
Naproxen—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	3.97e-05	0.000266	CcSEcCtD
Naproxen—Pruritus—Lisinopril—systemic scleroderma	3.92e-05	0.000263	CcSEcCtD
Naproxen—Vomiting—Mycophenolic acid—systemic scleroderma	3.91e-05	0.000262	CcSEcCtD
Naproxen—Haemoglobin—Methotrexate—systemic scleroderma	3.89e-05	0.000261	CcSEcCtD
Naproxen—Rash—Mycophenolic acid—systemic scleroderma	3.87e-05	0.00026	CcSEcCtD
Naproxen—Dermatitis—Mycophenolic acid—systemic scleroderma	3.87e-05	0.00026	CcSEcCtD
Naproxen—Hepatitis—Methotrexate—systemic scleroderma	3.87e-05	0.00026	CcSEcCtD
Naproxen—Haemorrhage—Methotrexate—systemic scleroderma	3.87e-05	0.00026	CcSEcCtD
Naproxen—Urticaria—Mycophenolate mofetil—systemic scleroderma	3.85e-05	0.000259	CcSEcCtD
Naproxen—Headache—Mycophenolic acid—systemic scleroderma	3.85e-05	0.000259	CcSEcCtD
Naproxen—Pharyngitis—Methotrexate—systemic scleroderma	3.84e-05	0.000258	CcSEcCtD
Naproxen—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	3.83e-05	0.000257	CcSEcCtD
Naproxen—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	3.83e-05	0.000257	CcSEcCtD
Naproxen—Nausea—Leflunomide—systemic scleroderma	3.83e-05	0.000257	CcSEcCtD
Naproxen—Urinary tract disorder—Methotrexate—systemic scleroderma	3.82e-05	0.000256	CcSEcCtD
Naproxen—Vision blurred—Prednisone—systemic scleroderma	3.8e-05	0.000255	CcSEcCtD
Naproxen—Urethral disorder—Methotrexate—systemic scleroderma	3.79e-05	0.000255	CcSEcCtD
Naproxen—Diarrhoea—Lisinopril—systemic scleroderma	3.79e-05	0.000254	CcSEcCtD
Naproxen—Ill-defined disorder—Prednisone—systemic scleroderma	3.74e-05	0.000251	CcSEcCtD
Naproxen—Visual impairment—Methotrexate—systemic scleroderma	3.73e-05	0.00025	CcSEcCtD
Naproxen—Anaemia—Prednisone—systemic scleroderma	3.72e-05	0.00025	CcSEcCtD
Naproxen—Angioedema—Prednisone—systemic scleroderma	3.68e-05	0.000247	CcSEcCtD
Naproxen—Dizziness—Lisinopril—systemic scleroderma	3.66e-05	0.000246	CcSEcCtD
Naproxen—Erythema multiforme—Methotrexate—systemic scleroderma	3.66e-05	0.000246	CcSEcCtD
Naproxen—Nausea—Mycophenolic acid—systemic scleroderma	3.65e-05	0.000245	CcSEcCtD
Naproxen—Malaise—Prednisone—systemic scleroderma	3.63e-05	0.000244	CcSEcCtD
Naproxen—Vertigo—Prednisone—systemic scleroderma	3.62e-05	0.000243	CcSEcCtD
Naproxen—Eye disorder—Methotrexate—systemic scleroderma	3.61e-05	0.000243	CcSEcCtD
Naproxen—Syncope—Prednisone—systemic scleroderma	3.61e-05	0.000243	CcSEcCtD
Naproxen—Tinnitus—Methotrexate—systemic scleroderma	3.61e-05	0.000242	CcSEcCtD
Naproxen—Cardiac disorder—Methotrexate—systemic scleroderma	3.59e-05	0.000241	CcSEcCtD
Naproxen—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	3.57e-05	0.00024	CcSEcCtD
Naproxen—Loss of consciousness—Prednisone—systemic scleroderma	3.54e-05	0.000238	CcSEcCtD
Naproxen—Vomiting—Lisinopril—systemic scleroderma	3.52e-05	0.000236	CcSEcCtD
Naproxen—Angiopathy—Methotrexate—systemic scleroderma	3.51e-05	0.000236	CcSEcCtD
Naproxen—Immune system disorder—Methotrexate—systemic scleroderma	3.49e-05	0.000235	CcSEcCtD
Naproxen—Rash—Lisinopril—systemic scleroderma	3.49e-05	0.000234	CcSEcCtD
Naproxen—Convulsion—Prednisone—systemic scleroderma	3.49e-05	0.000234	CcSEcCtD
Naproxen—Dermatitis—Lisinopril—systemic scleroderma	3.49e-05	0.000234	CcSEcCtD
Naproxen—Mediastinal disorder—Methotrexate—systemic scleroderma	3.49e-05	0.000234	CcSEcCtD
Naproxen—Asthenia—Mycophenolate mofetil—systemic scleroderma	3.48e-05	0.000234	CcSEcCtD
Naproxen—Hypertension—Prednisone—systemic scleroderma	3.48e-05	0.000234	CcSEcCtD
Naproxen—Chills—Methotrexate—systemic scleroderma	3.47e-05	0.000233	CcSEcCtD
Naproxen—Headache—Lisinopril—systemic scleroderma	3.47e-05	0.000233	CcSEcCtD
Naproxen—Pruritus—Mycophenolate mofetil—systemic scleroderma	3.43e-05	0.00023	CcSEcCtD
Naproxen—Arthralgia—Prednisone—systemic scleroderma	3.43e-05	0.00023	CcSEcCtD
Naproxen—Myalgia—Prednisone—systemic scleroderma	3.43e-05	0.00023	CcSEcCtD
Naproxen—Anxiety—Prednisone—systemic scleroderma	3.42e-05	0.00023	CcSEcCtD
Naproxen—Alopecia—Methotrexate—systemic scleroderma	3.42e-05	0.000229	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	3.41e-05	0.000229	CcSEcCtD
Naproxen—Discomfort—Prednisone—systemic scleroderma	3.39e-05	0.000228	CcSEcCtD
Naproxen—Mental disorder—Methotrexate—systemic scleroderma	3.39e-05	0.000228	CcSEcCtD
Naproxen—Erythema—Methotrexate—systemic scleroderma	3.37e-05	0.000226	CcSEcCtD
Naproxen—Malnutrition—Methotrexate—systemic scleroderma	3.37e-05	0.000226	CcSEcCtD
Naproxen—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	3.32e-05	0.000223	CcSEcCtD
Naproxen—Nausea—Lisinopril—systemic scleroderma	3.29e-05	0.000221	CcSEcCtD
Naproxen—Oedema—Prednisone—systemic scleroderma	3.29e-05	0.000221	CcSEcCtD
Naproxen—Anaphylactic shock—Prednisone—systemic scleroderma	3.29e-05	0.000221	CcSEcCtD
Naproxen—Infection—Prednisone—systemic scleroderma	3.27e-05	0.000219	CcSEcCtD
Naproxen—Shock—Prednisone—systemic scleroderma	3.23e-05	0.000217	CcSEcCtD
Naproxen—Nervous system disorder—Prednisone—systemic scleroderma	3.22e-05	0.000217	CcSEcCtD
Naproxen—Tachycardia—Prednisone—systemic scleroderma	3.21e-05	0.000215	CcSEcCtD
Naproxen—Dizziness—Mycophenolate mofetil—systemic scleroderma	3.21e-05	0.000215	CcSEcCtD
Naproxen—Skin disorder—Prednisone—systemic scleroderma	3.19e-05	0.000214	CcSEcCtD
Naproxen—Hyperhidrosis—Prednisone—systemic scleroderma	3.18e-05	0.000213	CcSEcCtD
Naproxen—Vision blurred—Methotrexate—systemic scleroderma	3.17e-05	0.000213	CcSEcCtD
Naproxen—Anorexia—Prednisone—systemic scleroderma	3.13e-05	0.00021	CcSEcCtD
Naproxen—Ill-defined disorder—Methotrexate—systemic scleroderma	3.12e-05	0.00021	CcSEcCtD
Naproxen—Anaemia—Methotrexate—systemic scleroderma	3.11e-05	0.000209	CcSEcCtD
Naproxen—Vomiting—Mycophenolate mofetil—systemic scleroderma	3.08e-05	0.000207	CcSEcCtD
Naproxen—Rash—Mycophenolate mofetil—systemic scleroderma	3.06e-05	0.000205	CcSEcCtD
Naproxen—Dermatitis—Mycophenolate mofetil—systemic scleroderma	3.05e-05	0.000205	CcSEcCtD
Naproxen—Headache—Mycophenolate mofetil—systemic scleroderma	3.04e-05	0.000204	CcSEcCtD
Naproxen—Malaise—Methotrexate—systemic scleroderma	3.04e-05	0.000204	CcSEcCtD
Naproxen—Vertigo—Methotrexate—systemic scleroderma	3.02e-05	0.000203	CcSEcCtD
Naproxen—Leukopenia—Methotrexate—systemic scleroderma	3.01e-05	0.000202	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Prednisone—systemic scleroderma	2.99e-05	0.000201	CcSEcCtD
Naproxen—Insomnia—Prednisone—systemic scleroderma	2.97e-05	0.0002	CcSEcCtD
Naproxen—Paraesthesia—Prednisone—systemic scleroderma	2.95e-05	0.000198	CcSEcCtD
Naproxen—Cough—Methotrexate—systemic scleroderma	2.94e-05	0.000197	CcSEcCtD
Naproxen—Convulsion—Methotrexate—systemic scleroderma	2.92e-05	0.000196	CcSEcCtD
Naproxen—Dyspepsia—Prednisone—systemic scleroderma	2.89e-05	0.000194	CcSEcCtD
Naproxen—Nausea—Mycophenolate mofetil—systemic scleroderma	2.88e-05	0.000193	CcSEcCtD
Naproxen—Chest pain—Methotrexate—systemic scleroderma	2.87e-05	0.000192	CcSEcCtD
Naproxen—Arthralgia—Methotrexate—systemic scleroderma	2.87e-05	0.000192	CcSEcCtD
Naproxen—Myalgia—Methotrexate—systemic scleroderma	2.87e-05	0.000192	CcSEcCtD
Naproxen—Decreased appetite—Prednisone—systemic scleroderma	2.86e-05	0.000192	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	2.85e-05	0.000191	CcSEcCtD
Naproxen—Fatigue—Prednisone—systemic scleroderma	2.83e-05	0.00019	CcSEcCtD
Naproxen—Discomfort—Methotrexate—systemic scleroderma	2.83e-05	0.00019	CcSEcCtD
Naproxen—Constipation—Prednisone—systemic scleroderma	2.81e-05	0.000189	CcSEcCtD
Naproxen—Confusional state—Methotrexate—systemic scleroderma	2.77e-05	0.000186	CcSEcCtD
Naproxen—Anaphylactic shock—Methotrexate—systemic scleroderma	2.75e-05	0.000185	CcSEcCtD
Naproxen—Infection—Methotrexate—systemic scleroderma	2.73e-05	0.000183	CcSEcCtD
Naproxen—Feeling abnormal—Prednisone—systemic scleroderma	2.71e-05	0.000182	CcSEcCtD
Naproxen—Nervous system disorder—Methotrexate—systemic scleroderma	2.69e-05	0.000181	CcSEcCtD
Naproxen—Thrombocytopenia—Methotrexate—systemic scleroderma	2.69e-05	0.000181	CcSEcCtD
Naproxen—Gastrointestinal pain—Prednisone—systemic scleroderma	2.69e-05	0.000181	CcSEcCtD
Naproxen—Skin disorder—Methotrexate—systemic scleroderma	2.67e-05	0.000179	CcSEcCtD
Naproxen—Hyperhidrosis—Methotrexate—systemic scleroderma	2.66e-05	0.000178	CcSEcCtD
Naproxen—Anorexia—Methotrexate—systemic scleroderma	2.62e-05	0.000176	CcSEcCtD
Naproxen—Urticaria—Prednisone—systemic scleroderma	2.61e-05	0.000175	CcSEcCtD
Naproxen—Abdominal pain—Prednisone—systemic scleroderma	2.6e-05	0.000175	CcSEcCtD
Naproxen—Body temperature increased—Prednisone—systemic scleroderma	2.6e-05	0.000175	CcSEcCtD
Naproxen—Hypotension—Methotrexate—systemic scleroderma	2.57e-05	0.000172	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	2.5e-05	0.000168	CcSEcCtD
Naproxen—Insomnia—Methotrexate—systemic scleroderma	2.48e-05	0.000167	CcSEcCtD
Naproxen—Paraesthesia—Methotrexate—systemic scleroderma	2.47e-05	0.000166	CcSEcCtD
Naproxen—Dyspnoea—Methotrexate—systemic scleroderma	2.45e-05	0.000164	CcSEcCtD
Naproxen—Somnolence—Methotrexate—systemic scleroderma	2.44e-05	0.000164	CcSEcCtD
Naproxen—Hypersensitivity—Prednisone—systemic scleroderma	2.42e-05	0.000163	CcSEcCtD
Naproxen—Dyspepsia—Methotrexate—systemic scleroderma	2.42e-05	0.000162	CcSEcCtD
Naproxen—Decreased appetite—Methotrexate—systemic scleroderma	2.39e-05	0.00016	CcSEcCtD
Naproxen—Gastrointestinal disorder—Methotrexate—systemic scleroderma	2.37e-05	0.000159	CcSEcCtD
Naproxen—Fatigue—Methotrexate—systemic scleroderma	2.37e-05	0.000159	CcSEcCtD
Naproxen—Asthenia—Prednisone—systemic scleroderma	2.36e-05	0.000158	CcSEcCtD
Naproxen—Pain—Methotrexate—systemic scleroderma	2.35e-05	0.000158	CcSEcCtD
Naproxen—Pruritus—Prednisone—systemic scleroderma	2.33e-05	0.000156	CcSEcCtD
Naproxen—Feeling abnormal—Methotrexate—systemic scleroderma	2.26e-05	0.000152	CcSEcCtD
Naproxen—Diarrhoea—Prednisone—systemic scleroderma	2.25e-05	0.000151	CcSEcCtD
Naproxen—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.25e-05	0.000151	CcSEcCtD
Naproxen—Urticaria—Methotrexate—systemic scleroderma	2.18e-05	0.000147	CcSEcCtD
Naproxen—Dizziness—Prednisone—systemic scleroderma	2.17e-05	0.000146	CcSEcCtD
Naproxen—Body temperature increased—Methotrexate—systemic scleroderma	2.17e-05	0.000146	CcSEcCtD
Naproxen—Abdominal pain—Methotrexate—systemic scleroderma	2.17e-05	0.000146	CcSEcCtD
Naproxen—Vomiting—Prednisone—systemic scleroderma	2.09e-05	0.00014	CcSEcCtD
Naproxen—Rash—Prednisone—systemic scleroderma	2.07e-05	0.000139	CcSEcCtD
Naproxen—Dermatitis—Prednisone—systemic scleroderma	2.07e-05	0.000139	CcSEcCtD
Naproxen—Headache—Prednisone—systemic scleroderma	2.06e-05	0.000138	CcSEcCtD
Naproxen—Hypersensitivity—Methotrexate—systemic scleroderma	2.02e-05	0.000136	CcSEcCtD
Naproxen—Asthenia—Methotrexate—systemic scleroderma	1.97e-05	0.000132	CcSEcCtD
Naproxen—Nausea—Prednisone—systemic scleroderma	1.95e-05	0.000131	CcSEcCtD
Naproxen—Pruritus—Methotrexate—systemic scleroderma	1.94e-05	0.000131	CcSEcCtD
Naproxen—Diarrhoea—Methotrexate—systemic scleroderma	1.88e-05	0.000126	CcSEcCtD
Naproxen—Dizziness—Methotrexate—systemic scleroderma	1.82e-05	0.000122	CcSEcCtD
Naproxen—Vomiting—Methotrexate—systemic scleroderma	1.75e-05	0.000117	CcSEcCtD
Naproxen—Rash—Methotrexate—systemic scleroderma	1.73e-05	0.000116	CcSEcCtD
Naproxen—Dermatitis—Methotrexate—systemic scleroderma	1.73e-05	0.000116	CcSEcCtD
Naproxen—Headache—Methotrexate—systemic scleroderma	1.72e-05	0.000116	CcSEcCtD
Naproxen—Nausea—Methotrexate—systemic scleroderma	1.63e-05	0.00011	CcSEcCtD
